Dear All,


FoRx Therapeutics is a recently incorporated privately-held company based in 
Basel, Switzerland. It is backed by a syndicate of investors that include the 
Novartis Venture Fund, Pfizer Ventures, M Ventures, Omega Funds and LSP Venture 
Capital. FoRx Therapeutics focuses on drugging key molecular targets involved 
in the DNA Replication Stress, as a new approach in the development of targeted 
anticancer drugs.



We are seeking a Biochemist/Crystallographer to crystallize protein-drug 
complexes.



Requirements are a PhD in Biochemistry, Structural Biology or related Field. 
Postdoc experience is optional. First author publication in a relevant journal 
is required.



The successful candidate for this position will be a highly motivated 
individual who can communicate effectively, contribute beyond their strict 
discipline, be flexible and responsive to the changing needs of a dynamic 
entrepreneurial organization and fit well in small agile biotech team.



FoRx Therapeutics encourages and supports a diverse work environment as an 
Equal Opportunity Employer, offers a stimulating work environment and a 
competitive compensation package.



Interested candidates should send a cover letter describing research interests 
and career goals, along with a Curriculum Vitae to:



[email protected] <mailto:[email protected]>



Kind regards,

Sotirios



- - -

Sotirios K. Sotiriou, PhD

Head of Biology & Co-Founder

WSJ350.3.05, Lichtstrasse 35

4056 Basel, Switzerland

Tel: +41 (0) 788733686

 <mailto:[email protected]> 
[email protected]

















--
This email has been checked for viruses by AVG.
https://www.avg.com

########################################################################

To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB&A=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

Reply via email to